LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

(2015) Toshihiko Doi et al.   ANTI-CANCER DRUGS

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus

(2015) S.-B. Koh et al.   CANCER RESEARCH

Will Targeting Chk1 Have a Role in the Future of Cancer Therapy?

(2015) Nandini Sakurikar et al.   JOURNAL OF CLINICAL ONCOLOGY

The fork and the kinase: A DNA replication tale from a CHK1 perspective

(2015) Marina A. González Besteiro et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

(2014) Emiliano Calvo et al.   INVESTIGATIONAL NEW DRUGS

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

(2013) Ryan Montano et al.   BMC CANCER

ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA

(2013) Luis Ignacio Toledo et al.   CELL

Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death

(2013) Christopher J Del Nagro et al.   CELL CYCLE

Checkpoint kinase 1 in DNA damage response and cell cycle regulation

(2013) Mallikarjun Patil et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Roles of Chk1 in cell biology and cancer therapy

(2013) Youwei Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

(2012) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

ATR signalling: more than meeting at the fork

(2011) Edward A. Nam et al.   BIOCHEMICAL JOURNAL

Unleashing Chk1 in cancer therapy

(2011) Laura Carrassa et al.   CELL CYCLE

Targeting the S and G2 checkpoint to treat cancer

(2011) Tao Chen et al.   DRUG DISCOVERY TODAY

A framework for variation discovery and genotyping using next-generation DNA sequencing data

(2011) Mark A DePristo et al.   NATURE GENETICS

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Fast and accurate short read alignment with Burrows-Wheeler transform

(2009) H. Li et al.   BIOINFORMATICS

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS